SCHEMBL5537376

SCHEMBL5537376

CC1(CN2CCN(C(=O)COc3ccc(Cl)cc3)CC2)Cn2cc([N+](=O)[O-])nc2O1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 6/20 0.53
KDM4E B2RXH2 3/20 0.51
ALDH1A1 P00352 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
ENPP2 Q13822 3/20 0.49
SLC6A2 P23975 2/20 0.45
SLC6A4 P31645 2/20 0.45
PTGS1 P23219 1/20 0.45
CACNA1C Q13936 1/20 0.45
SCN5A Q14524 1/20 0.45
KMT2A Q03164 1/20 0.43
MAPT P10636 3/20 0.42
LMNA P02545 3/20 0.42
POLB P06746 2/20 0.42
HPGD P15428 1/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ABCB11 O95342 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5537367 1.00 KCNH2 (0.53) KCNH2KDM4EALDH1A1SMN1; SMN2ENPP2
SCHEMBL5537817 0.92 KCNH2 (0.52) KCNH2KDM4EALDH1A1SMN1; SMN2SLC6A2
SCHEMBL5540651 0.91 KCNH2 (0.49) KCNH2KDM4EALDH1A1SMN1; SMN2ENPP2
SCHEMBL5534983 0.91 KCNH2 (0.49) KCNH2KDM4EALDH1A1SMN1; SMN2ENPP2
SCHEMBL5534657 0.87 KCNH2 (0.49) KCNH2KDM4EALDH1A1SMN1; SMN2SLC6A2
SCHEMBL5534653 0.87 KCNH2 (0.49) KCNH2KDM4EALDH1A1SMN1; SMN2SLC6A2
SCHEMBL5540156 0.86 KCNH2 (0.48) KCNH2KDM4EALDH1A1SMN1; SMN2SLC6A2
SCHEMBL5535628 0.85 KCNH2 (0.48) KCNH2KDM4EALDH1A1SMN1; SMN2SLC6A2
SCHEMBL5535633 0.85 KCNH2 (0.48) KCNH2KDM4EALDH1A1SMN1; SMN2SLC6A2
SCHEMBL5536518 0.85 SMN1; SMN2 (0.47) KCNH2ALDH1A1SMN1; SMN2SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KCNH2 3503/4885KDM4E 4854/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.